TRCT
MRNA icon

Tower Research Capital (TRC)’s Moderna MRNA Stock Holding History

Tower Research Capital (TRC)’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351K Sell
5,006
-28,722
-85% -$1.49M 0.01% 1275
2026
Q1 		$1.71M Buy
33,728
+15,851
+89% +$740K 0.04% 383
2025
Q4 		$527K Sell
17,877
-8,091
-31% -$220K 0.01% 805
2025
Q3 		$671K Buy
25,968
+17,483
+206% +$488K 0.02% 689
2025
Q2 		$234K Sell
8,485
-3,562
-30% -$93.8K 0.01% 1636
2025
Q1 		$473K Sell
12,047
-47,981
-80% -$1.7M 0.01% 865
2024
Q4 		$2.5M Buy
60,028
+43,364
+260% +$2.07M 0.05% 307
2024
Q3 		$1.11M Sell
16,664
-55,429
-77% -$5.09M 0.03% 498
2024
Q2 		$8.56M Buy
72,093
+43,763
+154% +$5.54M 0.14% 106
2024
Q1 		$3.02M Sell
28,330
-30,636
-52% -$3.09M 0.07% 196
2023
Q4 		$5.86M Buy
58,966
+38,132
+183% +$3.21M 0.07% 227
2023
Q3 		$2.15M Buy
20,834
+1,210
+6% +$135K 0.07% 291
2023
Q2 		$2.38M Buy
19,624
+12,633
+181% +$1.69M 0.08% 193
2023
Q1 		$1.07M Sell
6,991
-4,494
-39% -$741K 0.03% 407
2022
Q4 		$2.06M Sell
11,485
-66,984
-85% -$11M 0.09% 160
2022
Q3 		$9.28M Buy
78,469
+19,772
+34% +$3M 0.15% 123
2022
Q2 		$8.38M Sell
58,697
-55,552
-49% -$7.94M 0.19% 87
2022
Q1 		$19.7M Buy
114,249
+71,508
+167% +$12M 0.19% 100
2021
Q4 		$10.9M Buy
42,741
+21,125
+98% +$6.18M 0.19% 89
2021
Q3 		$8.32M Sell
21,616
-28,240
-57% -$10.4M 0.21% 64
2021
Q2 		$11.7M Buy
49,856
+25,898
+108% +$4.63M 0.3% 47
2021
Q1 		$3.14M Buy
23,958
+17,979
+301% +$2.61M 0.05% 329
2020
Q4 		$624K Sell
5,979
-5,203
-47% -$526K 0.02% 831
2020
Q3 		$791K Buy
11,182
+9,989
+837% +$696K 0.01% 1207
2020
Q2 		$77K Buy
+1,193
New +$65.3K ﹤0.01% 2689
2020
Q1 		– Sell
-10,017
Closed -$196K – 3574
2019
Q4 		$196K Buy
10,017
+5,491
+121% +$97.4K 0.02% 598
2019
Q3 		$72K Buy
+4,526
New +$66.9K ﹤0.01% 1544
2019
Q2 		– Sell
-3,709
Closed -$75K – 4056
2019
Q1 		$75K Buy
+3,709
New +$68.8K ﹤0.01% 1565

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Tower Research Capital (TRC)'s MRNA Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Moderna (MRNA) stake by 85% in Q2 2026, selling an estimated $1.49M and leaving 5,006 shares worth $351K. The position accounts for 0.01% of the portfolio, ranked #1275.

Tower Research Capital (TRC) first reported a position in MRNA in Q1 2019 and has held it in 28 quarters since. The position peaked at $19.7M in Q1 2022. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Tower Research Capital (TRC) held 5,006 shares of Moderna worth $351K as of Q2 2026.
  • Tower Research Capital (TRC) sold 28,722 Moderna shares in Q2 2026, an estimated $1.49M.
  • Moderna made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1275 holding.
  • Tower Research Capital (TRC) first reported a position in Moderna in Q1 2019 and has held it in 28 quarters since.
  • Tower Research Capital (TRC)'s Moderna position peaked at $19.7M in Q1 2022.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.